Anti-ACLY/ ACL/ ATPCL monoclonal antibody

Anti-ACLY/ ACL/ ATPCL antibody for FACS & in-vivo assay

Target products collectionGo to ACLY/ACLY products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T52189-Ab-1/ GM-Tg-hg-T52189-Ab-2Anti-Human ACLY monoclonal antibodyHuman
GM-Tg-rg-T52189-Ab-1/ GM-Tg-rg-T52189-Ab-2Anti-Rat ACLY monoclonal antibodyRat
GM-Tg-mg-T52189-Ab-1/ GM-Tg-mg-T52189-Ab-2Anti-Mouse ACLY monoclonal antibodyMouse
GM-Tg-cynog-T52189-Ab-1/ GM-Tg-cynog-T52189-Ab-2Anti-Cynomolgus/ Rhesus macaque ACLY monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T52189-Ab-1/ GM-Tg-felg-T52189-Ab-2Anti-Feline ACLY monoclonal antibodyFeline
GM-Tg-cang-T52189-Ab-1/ GM-Tg-cang-T52189-Ab-2Anti-Canine ACLY monoclonal antibodyCanine
GM-Tg-bovg-T52189-Ab-1/ GM-Tg-bovg-T52189-Ab-2Anti-Bovine ACLY monoclonal antibodyBovine
GM-Tg-equg-T52189-Ab-1/ GM-Tg-equg-T52189-Ab-2Anti-Equine ACLY monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg

Product Description

Catalog No.GM-Tg-hg-T52189-Ab-1/ GM-Tg-hg-T52189-Ab-2; GM-Tg-rg-T52189-Ab-1/ GM-Tg-rg-T52189-Ab-2;
GM-Tg-mg-T52189-Ab-1/ GM-Tg-mg-T52189-Ab-2; GM-Tg-cynog-T52189-Ab-1/ GM-Tg-cynog-T52189-Ab-2;
GM-Tg-felg-T52189-Ab-1/ GM-Tg-felg-T52189-Ab-2; GM-Tg-cang-T52189-Ab-1/ GM-Tg-cang-T52189-Ab-2;
GM-Tg-bovg-T52189-Ab-1/ GM-Tg-bovg-T52189-Ab-2; GM-Tg-equg-T52189-Ab-1/ GM-Tg-equg-T52189-Ab-2
Products NameAnti-ACLY monoclonal antibody
Target NameACLY
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
Products descriptionPre-made anti-ACLY benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


    Data / case study

    Click to get more Data / Case study about the product.

    Associated products

    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species ACLY/ ACL/ ATPCL VLP (virus-like particle) (Products Developing)
    ORF Viral VectorvGMLP005159human ACLY Lentivirus particle
    ORF Viral VectorpGMLP005159human ACLY Lentivirus plasmid

    Target information

    Target IDGM-T52189
    Target NameACLY
    Gene ID47,104112,24159,708501,607852,100422779,511135,100053195
    Gene Symbol and SynonymsA730098H14Rik,ACL,ACLY,ATPCL,CLATP
    Uniprot AccessionP53396,P16638,Q32PF2
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target
    Gene EnsemblENSG00000131473
    Target ClassificationN/A

    The target: ACLY, gene name: ACLY, also named as ACL, ATPCL, CLATP. ATP citrate lyase is the primary enzyme responsible for the synthesis of cytosolic acetyl-CoA in many tissues. The enzyme is a tetramer (relative molecular weight approximately 440,000) of apparently identical subunits. It catalyzes the formation of acetyl-CoA and oxaloacetate from citrate and CoA with a concomitant hydrolysis of ATP to ADP and phosphate. The product, acetyl-CoA, serves several important biosynthetic pathways, including lipogenesis and cholesterogenesis. In nervous tissue, ATP citrate-lyase may be involved in the biosynthesis of acetylcholine. Multiple transcript variants encoding distinct isoforms have been identified for this gene. [provided by RefSeq, Dec 2014].

    About Gmab


    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.